Annals of Behavioral Medicine

, Volume 42, Issue 3, pp 313–320

Treatment-Related Optimism Protects Quality of Life in a Phase II Clinical Trial for Metastatic Renal Cell Carcinoma

Original Article



Patients on clinical trials often experience declining quality of life (QOL). Little is known about the psychosocial variables that buffer against decline.


This study aims to examine correlations between psychosocial variables and QOL over the course of a clinical trial in patients with metastatic renal cell cancer.


At baseline, 114 participants completed measures of treatment-related optimism, social support, and QOL (Functional Assessment of Cancer Therapy-General). QOL was also assessed 2, 4, and 8 weeks after the start of treatment with low-dose or intermediate-dose interferon.


QOL decreased significantly in the intermediate-dose group but not in the low-dose group (p < .01). The decline was less severe for patients who had high rather than low treatment optimism (p = .03). A higher level of social support was significantly associated with higher baseline QOL (p < .05) but a more rapid decline in QOL over time (p < .01).


Treatment optimism was favorably associated with QOL.


Treatment-related optimism Social support Metastatic renal cell cancer Clinical trial 


  1. 1.
    Cella D: Beyond traditional outcomes: Improving quality of life in patients with renal cell carcinoma. Oncologist. 2011, 16 Suppl 2:23–31.PubMedCrossRefPubMedCentralGoogle Scholar
  2. 2.
    Ather MH, Masood N, Siddiqui T: Current management of advanced and metastatic renal cell carcinoma. Urol J. 2010, 7:1–9.PubMedGoogle Scholar
  3. 3.
    Cella D: Quality of life in patients with metastatic renal cell carcinoma: The importance of patient-reported outcomes. Cancer Treat Rev. 2009, 35:733–737.PubMedCrossRefGoogle Scholar
  4. 4.
    Kirchner H, Strumberg D, Bahl A, Overkamp F: Patient-based strategies for systemic treatment of metastatic renal cell carcinoma. Expert Rev Anticancer Ther. 2010, 10:585–596.PubMedCrossRefGoogle Scholar
  5. 5.
    Jonasch E, Pagliaro LC, Tannir N. M.: Long-term management of patients with metastatic renal cell carcinoma on targeted agents. Expert Rev Anticancer Ther. 2010, 10:1883–1889.PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Scheier MF, Carver CS: Dispositional optimism and physcial well-being: The influence of generalized outcome expectancies on health. J Pers. 1987, 55:169–210.PubMedCrossRefGoogle Scholar
  7. 7.
    Segerstrom SC, Taylor SE, Kemeny ME, Fahey JL: Optimism is associated with mood, coping, and immune change in response to stress. J Pers Soc Psychol. 1998, 74:1646–1655.PubMedCrossRefGoogle Scholar
  8. 8.
    Coyne JC, Tennen H: Positive psychology in cancer care: Bad science, exaggerated claims, and unproven medicine. Ann Behav Med. 2010, 39:16–26.PubMedCrossRefPubMedCentralGoogle Scholar
  9. 9.
    Greer S, Morris T, Pettingale KW, Haybittle JL: Psychological response to breast cancer and 15-year outcome. Lancet. 1990, 335:49–50.PubMedCrossRefGoogle Scholar
  10. 10.
    Carver CS, Smith RG, Antoni MH, et al.: Optimistic personality and psychosocial well-being during treatment predict psychosocial well-being among long-term survivors of breast cancer. Health Psychol. 2005, 24:508–516.PubMedCrossRefGoogle Scholar
  11. 11.
    Wimberly SR, Carver CS, Antoni MH: Effects of optimism, interpersonal relationships, and distress on psychosexual well-being among women with early stage breast cancer. Psychol Heal. 2008, 23:57–72.CrossRefGoogle Scholar
  12. 12.
    Matthews EE, Cook PF: Relationships among optimism, well-being, self-transcendence, coping, and social support in women during treatment for breast cancer. Psychooncology. 2009, 18:716–726.PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    Friedman LC, Kalidas M, Elledge R, et al.: Optimism, social support and psychosocial functioning among women with breast cancer. Psychooncology. 2006, 15:595–603.PubMedCrossRefGoogle Scholar
  14. 14.
    Cohen L, deMoor, C., Amato, R.J.,: The association between treatment-specific optimism and depressive symptomatology in patients enrolled in a phase I cancer clinical trial. Cancer. 2001, 91:1949–1955.PubMedCrossRefGoogle Scholar
  15. 15.
    Taylor SE: Adjustment to threatening events—A theory of cognitive adaptation. Am Psychol. 1983, 38:1161–1173.CrossRefGoogle Scholar
  16. 16.
    Taylor SE, Armor DA: Positive illusions and coping with adversity. J Pers. 1996, 64:873–898.PubMedCrossRefGoogle Scholar
  17. 17.
    Stiegelis HE, Hagedoorn M, Sanderman R, et al.: Cognitive adaptation: A comparison of cancer patients and healthy references. Br J Health Psychol. 2003, 8:303–318.PubMedCrossRefGoogle Scholar
  18. 18.
    Taylor SE, Falke RL, Shoptaw SJ, Lichtman RR: Social support, support groups, and the cancer patient. J Consult Clin Psychol. 1986, 54:608–615.PubMedCrossRefGoogle Scholar
  19. 19.
    Rosen NO, Knäuper B, DiDio P, Morrison E, Tabing R, Feldstain A, Amsel R, Mayrand MH, Franco EL, Rosberger Z: The impact of intolerance of uncertainty on anxiety after receiving an informational intervention about HPV: A randomised controlled study. Psychol Health. 2010, 25:651–668.PubMedCrossRefGoogle Scholar
  20. 20.
    Kreitler D, Peleg D, Ehrenfeld M: Stress, self-efficacy and quality of life in cancer patients. Psychooncology. 2007, 16,329-341.PubMedCrossRefGoogle Scholar
  21. 21.
    Tannir N, Cohen L, Wang X, et al.: Improved tolerability and quality of life with maintained efficacy using twice daily low-dose interferon α-2b. Cancer. 2006, 107,2254-2261.PubMedCrossRefGoogle Scholar
  22. 22.
    Motzer R, Bacik J, Murphy B, Russo P, Mazumdar R: Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002,20:289–296.PubMedCrossRefGoogle Scholar
  23. 23.
    Reed G.M., Kemeny M.E., Taylor S.E., Visscher B.R.: Negative HIV-specific expectations and AIDS-related bereavement as predictors of symptom onset in asymptomatic HIV-positive gay men. Health Psychol. 1999, 18:354–363.PubMedCrossRefGoogle Scholar
  24. 24.
    Landerman R, George LK, Campbell RT, Blazer DG: Alternative models of the stress buffering hypothesis. Am J Community Psychol. 1989, 17:625–642.PubMedCrossRefGoogle Scholar
  25. 25.
    Cella DF, Tulsky D, Gray G, et al.: The Functional Assessment of Cancer Therapy Scale: Development and validation of the general measure. J Clin Oncol. 1993, 11:570–579.PubMedGoogle Scholar
  26. 26.
    Cella DF, Zagari MJ, Vandoros C, et al.: Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population. J Clin Oncol. 2003, 2:366–373.CrossRefGoogle Scholar
  27. 27.
    Scheier MF, Carver CS, Bridges MW: Distinguishing optimism from neuroticism (and trait anxiety, self-mastery, and self-esteem): A reevaluation of the Life Orientation Test. J Pers Soc Psychol. 1994, 67:1063–1078.PubMedCrossRefGoogle Scholar
  28. 28.
    Singer JD, Willett JB: Applied longitudinal data analysis: Modeling change and event occurrence. New York: Oxford University Press, 2003.CrossRefGoogle Scholar
  29. 29.
    Kenn DA KD, Cook WL: Dyadic data analysis. New York: Guilford Press, 2006.Google Scholar
  30. 30.
    Wolfer R, Sang C: Comparing the SAS GLM and MIXED procedures for repeated measures. In: Proceedings of the Twentieth Annual SAS Users Group Conference, Cary, NC. Cary, NC: 1995.Google Scholar
  31. 31.
    Snijders T, Bosker R: Multilevel analysis. Thousand Oaks: Sage, 1999.Google Scholar
  32. 32.
    Preacher KJ, Curran PJ, Bauer DJ: Computational tools for probing interaction effects in multiple linear regression, multilevel modeling, and latent curve analysis. J Educ Behav Stat. 2006, 31:437–448.CrossRefGoogle Scholar
  33. 33.
    Taylor SE, Brown JD: Illusion and well-being: A social psychological perspective on mental health. Psychol Bull. 1988, 103:139–210.CrossRefGoogle Scholar
  34. 34.
    Thoits PA: Stress, coping, and social support process: Where are we? What next? Journal of Health and Social Behavior. 1995, 35:Extra issue: Forty years of medical sociology: The state of the art and directions for the future.Google Scholar
  35. 35.
    Daugherty C RM, Grochowski E, Stocking C, Kodish E, Mick R, et al.: Perceptions of cancer patients and their physicians involved in phase I trials. J Clin Oncol. 1995, 13(5):1062–1072.PubMedGoogle Scholar

Copyright information

© The Society of Behavioral Medicine 2011

Authors and Affiliations

  • Kathrin Milbury
    • 1
  • Nizar M. Tannir
    • 2
  • Lorenzo Cohen
    • 3
  1. 1.Department of Behavioral ScienceThe University of Texas MD Anderson Cancer CenterHoustonUSA
  2. 2.Department of Genitourinary Medical OncologyThe University of Texas MD Anderson Cancer CenterHoustonUSA
  3. 3.Department of General Oncology/Integrative Medicine ProgramThe University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations